Duyuru • Jun 05
Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ). Altor Equity Partners AB acquired Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024.Altor Equity Partners AB completed the acquisition of Remaining Assets of Re:NewCell AB (publ) from Re:NewCell AB (publ) on June 4, 2024. Duyuru • Jan 10
Re:NewCell AB Plans for Restructuring to Strengthen Organization Within Continuous Focus on Sales Re:NewCell AB announced that they are planning to start negotiations with the relevant trade unions regarding restructuring of the organization to improve efficiency while maintaining focus on sales. As part of the restructuring, the local authorities (Arbetsförmedlingen) will also be notified today. The planned restructuring will lead to a decrease in workforce of approximately 25%, just over 30 persons, and will also result in annual savings - reduction of personnel cost and other operating costs - of approximately 35 SEKm in total per annum when finalized. Duyuru • Dec 13
Peter Schulz Joins as Interim CFO at Re:NewCell AB (publ) Effective 1 January 2024 Re:NewCell AB (publ) announced Peter Schulz will join the company in the role of interim Chief Financial Officer (CFO) from 1 January 2024. He comes from a role as CFO at Pacific Basin Shipping (publ.) in Hong Kong, a position he has held for the past six years. Peter Schulz has extensive experience as CFO from both listed and private companies for the last 10 years. Prior to that Peter Schulz spent more than 15 years, and held senior positions, in investment banking in Stockholm, London and Hong Kong, among others with Royal Bank of Canada and ABN Amro. With his extensive and broad experience, he will contribute well to the management team and the company. Breakeven Date Change • Nov 22
Forecast to breakeven in 2025 The 3 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 30% per year to 2024. The company is expected to make a profit of kr12.8m in 2025. Average annual earnings growth of 82% is required to achieve expected profit on schedule. Reported Earnings • Nov 08
Third quarter 2023 earnings released: kr2.31 loss per share (vs kr2.99 loss in 3Q 2022) Third quarter 2023 results: kr2.31 loss per share (improved from kr2.99 loss in 3Q 2022). Revenue: kr86.1m (up kr83.1m from 3Q 2022). Net loss: kr94.5m (loss narrowed 6.9% from 3Q 2022). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 5.8% decline forecast for the Chemicals industry in the United Kingdom. New Risk • Nov 08
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings are forecast to decline by an average of 1.4% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr107m net loss in 2 years). Shareholders have been diluted in the past year (13% increase in shares outstanding). Market cap is less than US$100m (kr413.3m market cap, or US$37.8m). Duyuru • Nov 07
Re:NewCell AB (publ) to Report Fiscal Year 2023 Final Results on Apr 26, 2024 Re:NewCell AB (publ) announced that they will report fiscal year 2023 final results on Apr 26, 2024 New Risk • Oct 18
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: kr408m Forecast net loss in 2 years: kr121m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr121m net loss in 2 years). Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr352.3m market cap, or US$31.9m). Duyuru • Oct 18
Re:NewCell AB (publ) Announces CEO Changes Re:NewCell AB (publ) announced that the Board has appointed Magnus Håkansson as the new acting CEO. Magnus has solid experience from leading roles in the retail and fashion sector and from leadership in a listed environment. He will start on October 16, 2023 and replaces Patrik Lundström, who has been the company's CEO since 2019. Magnus Håkansson was born in 1963, has a degree in economics from the Stockholm School of Economics and an MBA from MIT Sloan School of Management. He started his career as a management consultant at McKinsey and has since held several leading roles in global growth companies in the retail sector, as well as the pulp industry, including many years with experience from a listed environment. He most recently came from a role as CEO of MediaMarkt Sweden. Breakeven Date Change • Oct 16
Forecast breakeven date pushed back to 2025 The 3 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% per year to 2024. The company is expected to make a profit of kr378.3m in 2025. Average annual earnings growth of 104% is required to achieve expected profit on schedule. New Risk • Oct 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr786m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Significant insider selling over the past 3 months (kr16m sold). Market cap is less than US$100m (kr566.9m market cap, or US$51.4m). Duyuru • Oct 13
Re:Newcell AB (Publ) Provides Earnings Guidance for the Third Quarter of 2023 Re:NewCell AB (publ) provided earnings guidance for the third quarter of 2023. For the quarter, the company expected to report Net loss of approximately SEK 105 million. Recent Insider Transactions • Oct 10
CEO & MD recently sold kr3.5m worth of stock On the 6th of October, Patrik Lundstrom sold around 109k shares on-market at roughly kr31.70 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth kr16m. Patrik has been a net seller over the last 12 months, reducing personal holdings by kr19m. Reported Earnings • Aug 30
Second quarter 2023 earnings released: kr2.82 loss per share (vs kr2.09 loss in 2Q 2022) Second quarter 2023 results: kr2.82 loss per share (further deteriorated from kr2.09 loss in 2Q 2022). Revenue: kr86.0m (up kr83.5m from 2Q 2022). Net loss: kr105.4m (loss widened 54% from 2Q 2022). Revenue is forecast to grow 78% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom. Breakeven Date Change • Aug 24
Forecast breakeven date pushed back to 2025 The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr233.9m in 2025. Average annual earnings growth of 73% is required to achieve expected profit on schedule. Recent Insider Transactions • Aug 01
CEO & MD recently sold kr16m worth of stock On the 27th of July, Patrik Lundstrom sold around 224k shares on-market at roughly kr71.36 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months. Duyuru • Jul 17
Re:NewCell AB (publ) Announces Toby Lawton to Leave His Position as CFO Re:NewCell AB (publ) Toby Lawton, CFO at Renewcell AB (publ), has announced that he will leave his position for a similar position in another company. Toby will continue to work as CFO until a successor has been appointed or at the latest until the end of the year. Duyuru • Jul 01
Re:Newcell AB (Publ) Provides Production from Renewcell 1 Guidance in June 2023 Re:NewCell AB (publ) provided production from Renewcell 1 guidance in June 2023. Production from Renewcell 1 is expected to reach 2,200-2,400 metric tons in June 2023, of which 2,100-2,300 metric tons are expected to be of prime quality and 2,200-2,400 metric tons are expected to be delivered to customers. The production in the month has been impacted by maintenance stops to upgrade and install new equipment in the shredding area. Reported Earnings • Apr 29
Full year 2022 earnings released: kr8.99 loss per share (vs kr4.33 loss in FY 2021) Full year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue is forecast to grow 71% p.a. on average during the next 3 years, compared to a 2.3% growth forecast for the Chemicals industry in the United Kingdom. Reported Earnings • Feb 16
Full year 2022 earnings released: kr8.99 loss per share (vs kr4.33 loss in FY 2021) Full year 2022 results: kr8.99 loss per share (further deteriorated from kr4.33 loss in FY 2021). Net loss: kr299.9m (loss widened 125% from FY 2021). Revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 1.7% growth forecast for the Chemicals industry in the United Kingdom. Breakeven Date Change • Feb 08
Forecast to breakeven in 2024 The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr51.6m in 2024. Average annual earnings growth of 66% is required to achieve expected profit on schedule. Breakeven Date Change • Nov 29
Forecast breakeven date pushed back to 2024 The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 22% per year to 2023. The company is expected to make a profit of kr118.9m in 2024. Average annual earnings growth of 72% is required to achieve expected profit on schedule. Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Breakeven Date Change • Oct 29
Forecast breakeven date pushed back to 2024 The 2 analysts covering Re:NewCell previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 65% per year to 2023. The company is expected to make a profit of kr122.1m in 2024. Average annual earnings growth of 75% is required to achieve expected profit on schedule. Reported Earnings • Oct 28
Third quarter 2022 earnings released: kr2.99 loss per share (vs kr0.80 loss in 3Q 2021) Third quarter 2022 results: kr2.99 loss per share (further deteriorated from kr0.80 loss in 3Q 2021). Net loss: kr101.5m (loss widened 314% from 3Q 2021). Revenue is forecast to grow 82% p.a. on average during the next 3 years, compared to a 8.6% decline forecast for the Chemicals industry in the United Kingdom. Reported Earnings • Aug 26
Second quarter 2022 earnings released: kr2.09 loss per share (vs kr0.76 loss in 2Q 2021) Second quarter 2022 results: kr2.09 loss per share (down from kr0.76 loss in 2Q 2021). Net loss: kr68.4m (loss widened 192% from 2Q 2021). Over the next year, revenue is forecast to grow 3,859% compared to a 21% decline forecast for the Chemicals industry in the United Kingdom. Board Change • Jun 02
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Recent Insider Transactions • May 24
Chief Financial Officer recently bought kr116k worth of stock On the 18th of May, Hugo Petit bought around 1k shares on-market at roughly kr116 per share. This was the largest purchase by an insider in the last 3 months. Hugo has been a buyer over the last 12 months, purchasing a net total of kr479k worth in shares. Reported Earnings • May 05
First quarter 2022 earnings released: kr1.75 loss per share (vs kr0.63 loss in 1Q 2021) First quarter 2022 results: kr1.75 loss per share (down from kr0.63 loss in 1Q 2021). Net loss: kr54.0m (loss widened 181% from 1Q 2021). Over the next year, revenue is forecast to grow 4,106% compared to a 17% decline forecast for the industry in the United Kingdom. Duyuru • May 05
Re:NewCell AB (publ) to Report Q1, 2023 Results on May 03, 2023 Re:NewCell AB (publ) announced that they will report Q1, 2023 results on May 03, 2023 Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Director Om Bhatia is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Breakeven Date Change • Mar 09
Forecast breakeven date moved forward to 2023 The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Recent Insider Transactions • Mar 03
Chief Growth Officer recently sold kr65k worth of stock On the 28th of February, Harald Cavalli-Bjorkman sold around 500 shares on-market at roughly kr129 per share. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought kr1.6m more than they sold in the last 12 months. Breakeven Date Change • Feb 19
Forecast breakeven date moved forward to 2023 The 2 analysts covering Re:NewCell previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of kr37.9m in 2023. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Duyuru • Feb 17
Re:NewCell AB (publ) to Report Q4, 2022 Results on Feb 15, 2023 Re:NewCell AB (publ) announced that they will report Q4, 2022 results on Feb 15, 2023 Reported Earnings • Feb 17
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Full year 2021 results: kr4.33 loss per share (down from kr3.34 loss in FY 2020). Net loss: kr133.4m (loss widened 94% from FY 2020). Revenue exceeded analyst estimates by 10%. Over the next year, revenue is forecast to grow 1,979% compared to a 3.7% decline forecast for the industry in the United Kingdom. Breakeven Date Change • Jan 26
Forecast to breakeven in 2024 The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Recent Insider Transactions • Jan 14
Chief Financial Officer recently bought kr80k worth of stock On the 12th of January, Hugo Petit bought around 425 shares on-market at roughly kr187 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr100k. Hugo has been a buyer over the last 12 months, purchasing a net total of kr319k worth in shares. Breakeven Date Change • Jan 07
Forecast to breakeven in 2024 The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Breakeven Date Change • Jan 01
Forecast to breakeven in 2024 The 2 analysts covering Re:NewCell expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of kr5.77m in 2024. Average annual earnings growth of 59% is required to achieve expected profit on schedule. Recent Insider Transactions • Dec 18
Chief Executive Officer recently bought kr100k worth of stock On the 14th of December, Patrik Lundstrom bought around 450 shares on-market at roughly kr221 per share. This was the largest purchase by an insider in the last 3 months. Patrik has been a buyer over the last 12 months, purchasing a net total of kr613k worth in shares. Reported Earnings • Nov 07
Third quarter 2021 earnings released: kr0.80 loss per share (vs kr0.81 loss in 3Q 2020) Third quarter 2021 results: Net loss: kr24.5m (loss widened 55% from 3Q 2020). Recent Insider Transactions • Jun 24
Plant Manager Ortviken recently bought kr108k worth of stock On the 21st of June, Henrik Dahlbom bought around 700 shares on-market at roughly kr155 per share. In the last 3 months, there was an even bigger purchase from another insider worth kr513k. Insiders have collectively bought kr1.5m more in shares than they have sold in the last 12 months. Recent Insider Transactions • Jun 13
Chief Executive Officer recently bought kr513k worth of stock On the 11th of June, Patrik Lundstrom bought around 3k shares on-market at roughly kr183 per share. This was the largest purchase by an insider in the last 3 months. This was Patrik's only on-market trade for the last 12 months. Recent Insider Transactions • May 24
Chief Financial Officer recently bought kr55k worth of stock On the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months. Executive Departure • May 22
Director has left the company On the 19th of May, Erik Karlsson's tenure in the role of Director ended. We don't have any record of a personal shareholding under Erik's name. A total of 3 executives have left over the last 12 months. Executive Departure • May 22
Director has left the company On the 19th of May, Henrik Norlin's tenure in the role of Director ended. We don't have any record of a personal shareholding under Henrik's name. A total of 3 executives have left over the last 12 months. Recent Insider Transactions • May 21
Interim Chief Financial Officer recently bought kr55k worth of stock On the 19th of May, Hugo Petit bought around 240 shares on-market at roughly kr228 per share. This was the largest purchase by an insider in the last 3 months. This was Hugo's only on-market trade for the last 12 months. Reported Earnings • May 07
First quarter 2021 earnings released First quarter 2021 results: Net loss: kr19.3m (loss widened 58% from 1Q 2020).